Biology Oriented Synthesis and Diversity Oriented Synthesis in Compound Collection Development

The Practice of Medicinal Chemistry

Volumn , Issue , 2008, Pages 187-209

  Kumar, Kamal ^a   Wetzel, Stefan ^a   Waldmann, Herbert ^a  

^a MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956310827     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374194-3.00009-3     Document Type: Chapter

References (124)

1. Dobson C.M. Chemical Space and Biology. Nature 2004, 432:824-828.
2. Bohacek R.S., McMartin C., Guida W.C. The art and practice of structure-based drug designing: a molecular modeling perspective. Med. Res. Rev. 1996, 16:3-50.
3. Augen J. The evolving role of information technology in the drug discovery process. Drug Discov. Today 2002, 7:315-323.
4. Blundell T.L., Jhoti H., Abell C. High-throughput crystallography for lead discovery in drug design. Nat. Rev. Drug Discov. 2002, 1:45-54.
5. Carr R., Hann M. The right road to drug discovery?. Mod. Drug Discov. 2002, 5:45-48.
6. Patani G.A., LaVoie E.J. Bioisosterism: a rational approach in drug design. Chem. Rev. 1996, 96:3147-3176.
7. Burke M.D., Schreiber S.L. A planning strategy for diversity-oriented synthesis. Angew. Chem. Int. Ed. 2004, 43:46-58.
8. Spring D.R. Diversity-oriented synthesis: a challenge for synthetic chemists. Org. Biomol. Chem. 2003, 1:3867-3870.
9. Mayer T.U., Kapoor T.M., Haggarty S.J., King R.W., Schreiber S.L., Mitchison T.J. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 1999, 286:971-974.
10. Lee D., Sello J.K., Schreiber S.L. A Strategy for macrocyclic ring closure and functionalization aimed toward split-pool syntheses. J. Am. Chem. Soc. 1999, 121:10648-10649.
11. Lee D., Sello J.K., Schreiber S.L. Pairwise use of complexity generating reactions in diversity-oriented organic synthesis. Org. Lett. 2000, 2:709-712.
12. DeWitt S.H., Kiely J.S., Stankovic C.J., Schroeder M.C., Cody D.M., Pavia M.R. Diversomers: an approach to nonpeptide, nonoligomeric chemical diversity. Proc. Natl. Acad. Sci. USA 1993, 90:6909-6913.
13. Pelish H.E., Westwood N.J., Feng Y., Kirchhausen T., Shair M.D. Use of biomimetic diversity-oriented synthesis to discover galanthamine-like molecules with biological properties beyond those of the natural product. J. Am. Chem. Soc. 2001, 123:6740-6741.
14. Dolle R.E., Nelson K.H. Comprehensive survey of combinatorial library synthesis: 1998. J. Comb. Chem. 1999, 1:235-282.
15. Dolle R.E. Comprehensive survey of combinatorial library synthesis: 1999. J. Comb. Chem. 2000, 2:383-433.
16. Dolle R.E. Comprehensive survey of combinatorial library synthesis: 2000. J. Comb. Chem. 2001, 3:477-517. (Since 1998, the comprehensive surveys of combinatorial library synthesis published by Dolle et al. are valuable source of information covering essentially all efforts in small molecule library synthesis).
17. Tan D.S., Foley M.A., Shair M.D., Schreiber S.L. Stereoselective synthesis of over two million compounds having structural features both reminiscent of natural products and compatible with miniaturized cell-based assays. J. Am. Chem. Soc. 1998, 120:8565-8566.
18. Masamune S., Choy W., Petersen J.S., Sita L.R. Double stereodifferentiation and a new strategy for stereocontrol in organic syntheses. Angew. Chem. Int. Ed. 1985, 24:1-30.
19. Masamune S. Recent advances in stereochemical control: multiple asymmetric induction. Heterocycles 1984, 21:107-136.
20. Ko S.Y., Lee A.W.M., Masamune S., Reed L.A., Sharpless K.B., Walker F.J. Total synthesis of the l-hexoses. Science 1983, 220:949-951.
21. Harrison B.A., Verdine G.L. The synthesis of an exhaustively stereo-diversified library of cis-1,5 enediols by silyl-tethered ring-closing metathesis. Org. Lett. 2001, 3:2157-2159.
22. Gierasch T.M., Shi Z., Verdine G.L. Extensively stereodiversified scaffolds for use in diversity-oriented library synthesis. Org. Lett. 2003, 5:621-624.
23. Su Q., Beeler A.B., Lobkovsky E., Porco J.A., Panek J.S. Stereochemical diversity through cyclodimerization: synthesis of polyketide-like macrolides. Org. Lett. 2003, 5:2149-2152.
24. Harrison B.A., Gierasch T.M., Neilan C., Pasternak G.W., Verdine G.L. High-affinity mu opoid receptor ligands discovered by the screening of an exhaustively stereodiversified library of 1,5-enediols. J. Am. Chem. Soc. 2002, 124:13352-13353.
25. Kim Y.-K., Arai M.A., Arai T., Lamenzo J.O., Dean E.F., Patterson N., Clemons P.A., Schreiber S.L. Relationship of stereo-chemical and skeletal diversity of small molecules to cellular measurement space. J. Am. Chem. Soc. 2004, 126:14740-14745.
26. Crews C.M., Mohan R. Small-molecule inhibitors of the cell cycle. Curr. Opin. Chem. Bio. 2000, 4:47-53.
27. Woo S., Squires N., Fallis A.G. Indium-mediated γ-pentadienylation of aldehydes and ketones: cross-conjugated trienes for diene-transmissive cycloadditions. Org. Lett. 1999, 1:573-575.
28. Kwon O., Park S.B., Schreiber S.L. Skeletal diversity via a branched pathway: efficient synthesis of 29,400 discrete, polycyclic compounds and their arraying into stock solutions. J. Am. Chem. Soc. 2002, 124:13402-13404.
29. Potuzak J.S., Moilanen S.B., Tan D.S. Discovery and applications of small molecule probes for studying biological processes. Biotechnol. Genet. Eng. Rev. 2004, 21:11-78.
30. Walters W.P., Namchuk M. A guide to drug discovery: designing screens: how to make your hits a hit. Nature Rev. Drug Discov. 2003, 2:259-266.
31. Stockwell B.R., Haggarty S.J., Schreiber S.L. High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications. Chem. Biol. 1999, 6:71-83.
32. Cohen J.L., Limon A., Miledi R., Chamberlin A.R. Design, synthesis, and biological evaluation of a scaffold for iGluR ligands based on the structure of (-)-dysiherbaine. Bioorg. Med. Chem. Lett. 2006, 16:2189-2194.
33. Kuruvilla F.G., Shamji A.F., Sternson S.M., Hergenrother P.J., Schreiber S.L. Dissecting glucose signalling with diversity-oriented synthesis and small-molecule microarrays. Nature 2002, 416:653-657.
34. Hotha S., Yarrow J.C., Yang J.G., Garrett S., Renduchintala K.V., Mayer T.U., Kapoor T.M. HR22C16: a potent small-molecule probe for the dynamics of cell division. Angew. Chem. Int. Ed. 2003, 42:2379-2382.
35. Spring D.R., Krishnan S., Blackwell H.E., Schreiber S.L. Diversity-oriented synthesis of biaryl-containing medium rings using a one bead/one stock solution platform. J. Am. Chem. Soc. 2002, 124:1354-1363.
36. Goess B.C., Hannoush R.N., Chan L.K., Kirchhausen T., Shair M.D. Synthesis of a 10,000-membered library of molecules resembling carpanone and discovery of vesicular traffic inhibitors. J. Am. Chem. Soc. 2006, 128:5391-5403.
37. Miertus S., Fassina G., Seneci P.F. Concepts of combinatorial chemistry and combinatorial technologies. Chem. Listy 2000, 94:1104-1110.
38. Smith J.M. Natural selection and the concept of a protein space. Nature 1970, 225:563-564.
39. Russell R.B., Sasieni P.D., Sternberg M.J.E. Supersites within superfolds. Binding site similarity in the absence of homology. J. Mol. Biol. 1998, 282:903-918.
40. Schmitt S., Kuhn D., Klebe G. A new method to detect related function among proteins independent of sequence and fold homology. J. Mol. Biol. 2002, 323:387-406.
41. Rush T.S., Grant J.A., Mosyak L., Nicholls A. A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. J. Med. Chem. 2005, 48:1489-1495.
42. Shah A.V., Walters W.P., Murcko M.A. Can we learn to distinguish between drug-like and nondrug-like molecules?. J. Med. Chem. 1998, 41:3314-3324.
43. Walters W.P., Shah A.V., Murcko M.A. Recognizing molecules with drug-like properties. Curr. Opin. Chem. Biol. 1999, 3:384-387.
44. Langer T., Hoffmann R.D. Pharmacophores and Pharmacophore Searches in the Series of Methods and Principles in Medicinal Chemistry 2006, 32. Wiley-VCH, Weinheim, published by R. Mannhold, H. Kubinyi, G. Folkers, 1. edition.
45. Noeren-Mueller A., Reis-Correa I., Prinz H., Rosenbaum C., Saxena K., Schwalbe H.J., Vestweber D., Cagna G., Schunk S., Schwarz O., Schiewe H., Waldmann H. Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis. Proc. Nat. Acad. Sci. USA 2006, 103:10606-10611.
46. Reis-Correa I., Noeren-Mueller A., Ambrosi H.D., Jakupovic S., Saxena K., Schwalbe H., Kaiser M., Waldmann H. Identification of inhibitors for mycobacterial protein tyrosine phosphatase B (MptpB) by biology-oriented synthesis (BIOS). Chem. Asian J 2007,, 2, 1109-1126.
47. Koch M.A., Schuffenhauer A., Scheck M., Wetzel S., Casaulta M., Odermatt A., Ertl P., Waldmann H. Charting biologically rele-vant chemical space: a structural classification of natural products (SCONP). Proc. Natl. Acad. Sci. USA 2005, 102:17272-17277.
48. Feher M., Schmidt J.M. Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J. Chem. Inf. Comput. Sci. 2003, 43:218-227.
49. Newman D.J., Cragg G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 2007, 70:461-477.
50. Evans B.E., Rittle K.E., Bock M.G., DiPardo R.M., Freidinger R.M., Whitter W.L., Lundell G.F., Veber D.F., Anderson P.S., Chang R.S.LV., Lotti J., Cerino D.J., Chen T.B., Kling P.J., Kunkel K.A., Springer J.P., Hirshfieldt J. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 1988, 31:2235-2246.
51. Dictionary of Natural Products (Chapman & Hall/CRC Informa, London), Version 14:2, 2005.
52. Brown R.D., Martin Y.C. Use of structure-activity data to compare structure-based clustering methods and descriptors for use in compound selection. J. Chem. Inf. Comp. Sci. 1996, 36:572-584.
53. Matter H., Poetter T. Comparing 3D pharmacophore triplets and 2D fingerprints for selecting diverse compound subsets. J. Chem. Inf. Comp. Sci. 1999, 39:1211-1225.
54. Robert P.S., Simon K.K. Why do we need so many chemical similarity search methods?. Drug Discov. Today 2002, 7:903-911.
55. Schuffenhauer A., Ertl P., Roggo S., Wetzel S., Koch M.A., Waldmann H. The scaffold tree-visualization of the scaffold universe by hierarchical scaffold classification. J. Chem. Inf. Model 2007, 47:47-58.
56. Thomson Scientific, Derwent World Drug Index, London, UK.
57. Barun O., Sommer S., Waldmann H. Asymmetric solid-phase synthesis of 6,6-spiroketals. Angew. Chem. Int. Ed. 2004, 43:3195-3199.
58. Barun O., Kumar K., Sommer S., Langerak A., Mayer T.U., Mueller O., Waldmann H. Natural product-guided synthesis of a spiroacetal collection reveals modulators of tubulin cytoskeleton integrity. Eur. J. Org. Chem 2005, 4773-4788.
59. Sommer S., Waldmann H. Solid phase synthesis of a spiro[5.5]ketal library. Chem. Commun 2005, 5684-5686.
60. Mamane V., Garcia A.B., Umarye J.D., Lessmann T., Sommer S., Waldmann H. Stereoselective allylation of aldehydes on solid support and its application in biology-oriented synthesis (BIOS). Tetrahedron 2007, 63:5754-5767.
61. Garcia A.B., Lessmann T., Umarye J.D., Mamane V., Sommer S., Waldmann H. Stereocomplementary synthesis of a natural product-derived compound collection on a solid phase. Chem. Commun 2006, 3868-3870.
62. Umarye J.D., Lessmann T., Garcia A.B., Mamane V., Sommer S., Waldmann H. Biology-oriented synthesis of stereochemically diverse natural-product-derived compound collections by iterative allylations on a solid support. Chem. Eur. J. 2007, 13:3305-3319.
63. Bialy L., Waldmann H. Synthesis of the protein phosphatase 2A inhibitor (4S,5S,6S,10S,11S,12S)-cytostatin. Angew. Chem. Int. Ed. 2002, 41:1748-1751.
64. Bialy L., Waldmann H. Total synthesis and biological evaluation of the protein phosphatase 2A inhibitor cytostatin and analogues. Chem. Eur. J. 2004, 10:2759-2780.
65. Lessmann T., Leuenberger M.G., Menninger S., Lopez-Canet M., Müller O., Huemmer S., Bormann J., Korn K., Fava E., Zerial M., Mayer T.U., Waldmann H. Natural product-derived modulators of cell cycle progression and viral entry by enantioselective oxa diels-alder reactions on the solid phase. Chem. Biol. 2007, 14:443-451.
66. Sanz M.A., Voigt T., Waldmann H. Enantioselective catalysis on the solid phase: synthesis of natural product-derived tetrahydropyrans employing the enantioselective oxa-Diels-Alder reaction. Adv. Synth. Cat. 2006, 348:1511-1515.
67. Meseguer B., Alonso-Díaz D., Griebenow N., Herget T., Waldmann H. Natural product synthesis on polymeric supports-synthesis and biological evaluation of an indolactam library. Angew. Chem. Int. Ed. 1999, 38:2902-2906.
68. Rosenbaum C., Baumhof P., Mazitschek R., Müller O., Giannis A., Waldmann H. Synthesis and biological evaluation of an indomethacin library reveals a new class of angiogenesis-related kinase inhibitors. Angew. Chem. Int. Ed. 2004, 43:224-228.
69. Rosenbaum C., Katzka C., Marzinzik A., Waldmann H. Traceless Fischer indole synthesis on the solid phase. Chem. Commun 2003, 1822-1823.
70. Ganesan A. Recent developments in combinatorial organic synthesis. Drug Discov. Today 2002, 7:47-55.
71. Arya P., Baek M.-G. Natural-product-like chiral derivatives by solid phase synthesis. Curr. Opin. Chem. Biol. 2001, 5:292-301.
72. Wessjohann L.A. Synthesis of natural-product-based compound libraries. Curr. Opin. Chem. Biol. 2000, 4:303-309.
73. Mentel M., Breinbauer R. Combinatorial solid phase natural product chemistry. Top. Curr. Chem 2007,, 278, 209-241.
74. Whitford D. Proteins, Structure and Function 2005, John Wiley & Sons, pp. 56-57. 1st edition.
75. Grant A., Lee D., Orengo C. Progress towards mapping the universe of protein folds. Genome Biol. 2004, 5:107.
76. Koonin E.V., Wolf Y.I., Karev G.P. The structure of the protein universe and genome evolution. Nature 2002, 420:218-223.
77. Leonov H., Mitchell J.S.B., Arkin I.T. Monte Carlo estimation of the number of possible protein folds: effects of sampling bias and folds distributions. Proteins 2003, 51:352-359.
78. Coulson A.F.W., Moult J. A unifold, mesofold, and superfold model of protein fold use. Proteins 2002, 46:61-71.
79. Murzin A.G., Brenner S.E., Hubbard T., Chothia C. SCOP: a structural classification of proteins database for the investigation of sequences and structures. J. Mol. Biol. 1995, 247:536-540.
80. Andreeva A., Howorth D., Brenner S.E., Hubbard T.J.P., Chothia C., Murzin A.G. SCOP database in 2004: refinements integrate structure and sequence family data. Nucl. Acids Res. 2004, 32:D226-D229.
81. Statistics taken from the SCOP website, (). http://scop.mrclmb.cam.ac.uk/scop/count.htm#scop-1.71.
82. Grishin N.V. Fold change in evolution of protein structures. J. Struc. Biol. 2001, 134:167-185.
83. Ponting C.P., Schultz J., Copley R.R., Andrade M.A., Bork P. Evolution of domain families. Adv. Protein Chem. 2000, 54:185-244.
84. Apic G., Gough J., Teichmann S.A. An insight into domain combinations. Bioinformatics 2001, 17(Suppl. 1):S83-S89. (Oxford, England).
85. Chothia C., Gough J., Vogel C., Teichmann S.A. Evolution of the protein repertoire. Science 2003, 300:1701-1703.
86. Liu J., Rost B. Domains, motifs and clusters in the protein universe. Curr. Opin. Chem. Biol. 2003, 7:5-11.
87. Lee D., Grant A., Buchan D., Orengo C. A structural perspective on genome evolution. Curr. Opin. Struc. Biol. 2003, 13:359-369.
88. Koch M.A., Breinbauer R., Waldmann H. Protein structure similarity as guiding principle for combinatorial library design. Biol. Chem. 2003, 384:1265-1272.
89. Koch M.A., Wittenberg L.-O., Basu S., Jeyaraj D.A., Gourzoulidou E., Reinecke K., Odermatt A., Waldmann H. Compound library development guided by protein structure similarity clustering and natural product structure. Proc. Natl. Acad. Sci. USA 2004, 101:16721-16726.
90. Koch M.A., Waldmann H. Natural product-derived compounds libraries and protein structure similarity as guiding principles for the discovery of drug candidates. Chemogenomics in Drug Discovery: A Medicinal Chemistry Perspective 2004, 377-403. Wiley-VCH. H. Kubinyi, G. Müller (Eds.).
91. Koch M.A., Waldmann H. Protein structure similarity clustering and natural product structure as guiding principles in drug discovery. Drug Discov. Today 2005, 10:471-483.
92. Balamurugan R., Dekker F.J., Waldmann H. Design of compound libraries based on natural product scaffolds and protein structure similarity clustering (PSSC). Mol. BioSyst. 2005, 1:36-45.
93. Dekker F.J., Koch M.A., Waldmann H. Protein structure similarity clustering (PSSC) and natural product structure as inspiration sources for drug development and chemical genomics. Curr. Opin. Chem. Bio. 2005, 9:232-239.
94. Dekker F.J., Wetzel S., Waldmann H. Natural product scaffolds and protein structure similarity clustering (PSSC) as inspiration sources for compound library design in chemogenomics and drug development. Chemogenomics 2006, 59-84.
95. Stark A., Shkumatov A., Russell R.B. Finding functional sites in structural genomics. Proteins 2004, 12:1405-1412.
96. Russell R.B., Sasieni P.D., Sternberg M.J.E. Supersites within superfolds. Binding site similarity in the absence of homology. J. Mol. Biol. 1998, 282:903-918.
97. Jones S., Thornton J.M. Searching for functional sites in protein structures. Curr. Opin. Chem. Biol. 2004, 8:3-7.
98. Anantharaman V., Aravind L., Koonin E.V. Emergence of diverse biochemical activities in evolutionarily conserved structural scaffolds of proteins. Curr. Opin. Chem. Biol. 2003, 7:12-20.
99. Lamb S.S., Wright G.D. Accessorizing natural products: adding to nature's toolbox. Proc. Natl. Acad. Sci. USA 2005, 102:519-520.
100. Holm L., Sander C. Dali/FSSP classification of three-dimensional protein folds. Nucl. Acids Res. 1997, 25:231-234.
101. Shindyalov I.N., Bourne P.E. Protein structure alignment by incremental combinatorial extension (CE) of the optimal path. Protein Engin. 1998, 11:739-747.
102. Shindyalov I.N., Bourne P.E. A database and tools for 3-D protein structure comparison and alignment using the combinatorial extension (CE) algorithm. Nucl. Acids Res. 2001, 29:228-229.
103. Gunasekera S.P., McCarthy P.J., Kelly-Borges M., Lobkovsky E., Clardy J. Dysidiolide: a novel protein phosphatase inhibitor from the Caribbean sponge Dysidea etheria de Laubenfels. J. Am. Chem. Soc. 1996, 118:8759-8760.
104. Lyon M.A., Ducruet A.P., Wipf P., Lazo J. Dual-specificity phosphatases as targets for antineoplastic agents. Nature Rev. Drug Discov. 2002, 1:961-976.
105. Fauman E.B., Cogswell J.P., Lovejoy B., Rocque W.J., Holmes W., Montana V.G., Piwnica-Worms H., Rink M.J., Saper M.A. Crystal structure of the catalytic domain of the human cell cycle control phosphatase, Cdc25A. Cell 1998, 93:617-625.
106. Bialy L., Waldmann H. Inhibitors of protein tyrosine phosphatases: next-generation drugs?. Angew. Chem. Int. Ed. 2005, 44:3814-3839.
107. Racchi M., Mazzucchelli M., Porrello E., Lanni C., Govoni S. Acetyl-cholinesterase inhibitors: novel activities of old molecules. Pharma. Res. 2004, 50:441-451.
108. Walker B.R., Seckl J.R. 11-β-Hydroxysteroiddehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative disease. Expert Opin. Therap. Targets 2003, 7:771-783.
109. Chrousos G.P. Is 11-beta-hydroxysteroid dehydrogenase type 1 a good therapeutic target for blockade of glucocorticoid actions?. Proc. Natl. Acad. Sci. USA 2004, 101:6329-6330.
110. Ross S.A., Gulve E.A., Wang M. Chemistry and biochemistry of type 2 diabetes. Chem. Rev. 2004, 104:1255-1282.
111. Sandeep T.C., Yau J.L.W., MacLullich A.M.J., Noble J., Deary I.J., Walker B.R., Seckl J.R. 11-β-Hydroxysteroiddehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc. Natl. Acad. Sci. USA 2004, 101:6734-6739.
112. Nicolaou K.C., Evans R.M., Roecker A.J., Hughes R., Downes M., Pfefferkorn J.A. Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries. Org. Biomol. Chem. 2003, 1:908-920.
113. Nicolaou K.C., Pfefferkorn J.A., Roecker A.J., Cao G.Q., Barluenga S., Mitchell H.J. Natural product-like combinatorial libraries based on privileged structures. 1. General principles and solid-phase synthesis of benzopyrans. J. Am. Chem. Soc. 2000, 122:9939-9953.
114. Nicolaou K.C., Pfefferkorn J.A., Mitchell H.J., Roecker A.J., Barluenga S., Cao G.-Q., Affleck R.L., Lillig J.E. Natural product-like combinatorial libraries based on privileged structures. 2. Construction of a 10,000-membered benzopyran library by directed split-and-pool chemistry using NanoKans and optical encoding. J. Am. Chem. Soc. 2000, 122:9954-9967.
115. Downes M., Verdecia M.A., Roecker A.J., Hughes R., Hogenesch J.B., Kast-Woelbern H.R., Bowman M.E., Ferrer J.-L., Anisfeld A.M., Edwards P.A., Rosenfeld J.M., Alvarez J.G.A., Noel J.P., Nicolaou K.C., Evans R.M. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol. Cell 2003, 11:1079-1092.
116. Robinson-Rechavi M., Escriva G.H., Laudet V. The nuclear receptor superfamily. J. Cell Sci. 2003, 116:585-586.
117. Gronemeyer H., Gustafsson J.A., Laudet V. Principles for modulation of the nuclear receptor superfamily. Nature Rev. Drug Discov. 2004, 3:950-964.
118. Jordan V.C. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 2004, 5:207-213.
119. Alarcon de la Lastra C., Sanchez-Fidalgo S., Villegas I., Motilva V. New pharmacological perspectives and therapeutic potential of PPAR-gamma agonists. Curr. Pharma. Design 2004, 10:3505-3524.
120. Dang Z.C., Audinot V., Papapoulos S.E., Boutin J.A., Loewik C.W.G.M. Peroxisome proliferator-activated receptor γ(PPARγ) as a molecular target for the soy phytoestrogen genistein. J. Biol. Chem. 2003, 278:962-967.
121. Van Gaal L., Scheen A.J. Are all glitazones the same?. Diabetes/Metab. Res. Rev. 2002, 18(Suppl. 2):S1-S4.
122. Gunasekera S.P., McCarthy P.J., Kelly-Borges M., Lobkovsky E., Clardy J. Dysidiolide: a novel protein phosphatase inhibitor from the Caribbean sponge Dysidea etheria de Laubenfels. J. Am. Chem. Soc. 1996, 118:8759-8760.
123. Charette B.D., MacDonald R.G., Wetzel S., Berkowitz D.B., Waldmann H. Protein structure similarity clustering: dynamic treatment of PDB structures facilitates clustering. Angew. Chem. Int. Ed. 2006, 45:7766-7770.
124. Leßmann T., Waldmann H. Enantioselective synthesis on the solid phase. Chem. Commun. 2006, 3380-3389.